Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reimbursement As Important As Regulatory Risks In Investment Decisions – Venture Capitalist

This article was originally published in The Pink Sheet Daily

Executive Summary

Venture capitalists are considering whether payers will pay and what reimbursement codes are available as they assess whether to put their money in companies with new medical products, a St. Louis venture capitalist tells regulatory affairs specialists in Seattle Oct. 28.

You may also be interested in...



PDUFA V: Accelerated Approval Expansion May Outshine Rare Disease Improvements

Rare disease advocate says the focus should be on ensuring the accelerated approval expansion and surrogate endpoint guidances become FDA priorities as the rare disease drug program is set to grow under PDUFA V.

How Bad Are Biomedical Innovation Problems? Metrics Needed To Know For Sure

Panel at Brookings Institution conference says there is no comprehensive measure and the issue is more complex than just tracking R&D spending and FDA approvals.

Drug Developers Facing "Unsettled" Period Of 5 To 10 Years As CER Environment Evolves, FDA's Woodcock Says

The growing emphasis on comparative effectiveness research as well as the many unknowns on how the process is going to evolve could create a decade of unsettlement for drug development, FDA's Janet Woodcock said

Topics

UsernamePublicRestriction

Register

PS073434

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel